Enliven Therapeutics
ELVN
33 hedge funds and large institutions have $257M invested in Enliven Therapeutics in 2020 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 23 increasing their positions, 3 reducing their positions, and 2 closing their positions.
667% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 3
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
13% more capital invested
Capital invested by funds: $228M → $257M (+$28.6M)
3% more funds holding
Funds holding: 32 → 33 (+1)
0.54% more ownership
Funds ownership: 16.2% → 16.74% (+0.54%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.82M |
| 2 |
BlackRock
New York
|
+$2.2M |
| 3 |
DM
Deerfield Management
New York
|
+$1.26M |
| 4 |
State Street
Boston,
Massachusetts
|
+$866K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$444K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
California Public Employees Retirement System
Sacramento,
California
|
-$460K |
| 2 |
Renaissance Technologies
New York
|
-$249K |
| 3 |
SG Americas Securities
New York
|
-$134K |
| 4 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$68.2K |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$19.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SO
26
STRS Ohio
Columbus,
Ohio
| $28K | – | – | – |
|
27
UBS Group
Zurich,
Switzerland
| $25K | +$23.4K | +279 | New |
|
28
Legal & General Group
London,
United Kingdom
| $19K | +$4.87K | +58 | +37% |
|
29
Bank of Montreal
Toronto,
Ontario, Canada
| $17K | +$20.5K | +244 | +428% |
|
|
AIP
30
Ameritas Investment Partners
Lincoln,
Nebraska
| $10K | – | – | – |
|
31
Royal Bank of Canada
Toronto,
Ontario, Canada
| $9K | +$8.31K | +99 | +3,300% |
|
|
PAM
32
Panagora Asset Management
Boston,
Massachusetts
| $3K | +$2.6K | +31 | New |
|
|
AIG
33
American International Group
New York
| $98 | +$31.4K | +374 | +51% |
|
|
34
Renaissance Technologies
New York
| – | -$249K | -3,056 | Closed |
|
|
35
SG Americas Securities
New York
| – | -$134K | -1,642 | Closed |
|
ELVN Hedge Fund Activity: Q4 2020 in Review
33 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Enliven Therapeutics (ELVN) for Q4 2020, worth a combined $257M — up 13% from $228M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ELVN positions and 2 closed out — a net gain of 1 holder — while 23 added to existing stakes and 3 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $2.82M. The largest seller was California Public Employees Retirement System, cutting an estimated $460K.
- 33 institutional investors held Enliven Therapeutics (ELVN) as of Q4 2020, up from 32 in Q3 2020.
- Funds reported $257M of Enliven Therapeutics stock for Q4 2020, up 13% quarter-over-quarter.
- 3 funds opened new Enliven Therapeutics positions in Q4 2020 and 2 closed out, a net change of +1 holder.
- The largest Enliven Therapeutics buyer in Q4 2020 was Fidelity Investments, an estimated $2.82M added.
- The largest Enliven Therapeutics seller in Q4 2020 was California Public Employees Retirement System, an estimated $460K sold.
Based on aggregated 13F filings for Q4 2020.